KHPG(SZ:002773)2022-12-06 02:31Group 1: Company Performance - The company reported a net profit growth of 25.98% in 2016 compared to the previous year [6] - For 2017, the company expects revenue and net profit to grow by 12-22% and 15-28% respectively compared to 2016 [6] Group 2: Product and Market Insights - The market for diabetic retinopathy, a new indication for the drug Langmu, accounts for 40%-50% of eye diseases, indicating significant market potential [2] - The company has not conducted precise market capacity assessments for future products [2] Group 3: Financial Reporting and Costs - The company allocated over 80 million yuan for poverty alleviation efforts in 2016, which was recorded as non-operating expenses [2] - Management expenses for 2016 were reported to be over 80 million yuan, with a significant portion attributed to equity incentives [4] Group 4: Research and Development - The company is focused on ophthalmology as its core treatment area, ensuring that new drug development aligns with this focus [3] - The clinical trial for the drug Kangbai Xip in the U.S. is currently in progress, with the selection of a CRO and confirmation of clinical protocols ongoing [3] Group 5: Market Strategy and Competition - The company is committed to maintaining its market strategy and will adjust promotional expenses based on market conditions, especially if Langmu is included in the national medical insurance directory [4] - The impact of price reductions on the drug Leizhu single antibody is acknowledged, and the company is strategizing to mitigate these effects [5]